Journal rankings · indicator year 2003
Choose a field to open its ranking, or a journal to find its row in its subfield’s list.
Subfield ranking · 2003
Oncology journal rankings 2003
103 ranked journals · Subfield in Medicine
Oncology has 103 ranked journals in 2003. The median OJR rose 0.10 on 2002 to 0.80, below the world average of 1.00; Q1 starts at OJR 1.37. The top three are CA A Cancer Journal for Clinicians, Cancer Cell, and Nature Medicine.
Ranks and citation indicators: 2003. Journal access status and listed APC: source snapshot September 23, 2026.
Journals whose main subfield sits in this category and that published at least 30 citable documents (articles, reviews and conference papers) in 2000–2002, the window the 2003 score is computed on.
The OpenJournalRank Indicator (OJR) is a free, publicly available metric of a journal’s field-normalized citation impact, computed from open OpenAlex citation data. It compares citations to a journal’s papers from the previous three years with the world average for papers of the same subfield, year and type, so 1.00 is the world average and values can be compared across fields. It is computed with the NCI3 method.
The middle OJR among ranked journals in this category: half score higher, half lower. 1.00 is the world average for papers of the same subfield, year and type.
The dot is this category, the solid tick is the median of all ranked journals and the dashed line is the world average.
Share of ranked journals in this category that are fully open access, so every paper is free to read. Hybrid journals, which sell subscriptions and open single papers for a fee, are not counted.
Median list price of the article processing charge, in US dollars, among ranked journals in this category that list a price above zero. Journals with a listed APC of $0 and journals with no known price are left out of this median. The At a glance table below gives a second median that includes the $0 prices.
Subfields of Medicine (42)
- Surgery378
- Pulmonary and Respiratory Medicine140
- Cardiology and Cardiovascular Medicine128
- Public Health, Environmental and Occupational Health128
- Oncology103
- Epidemiology89
- Infectious Diseases82
- Psychiatry and Mental health82
- Radiology, Nuclear Medicine and Imaging69
- Neurology68
- Physiology67
- Endocrinology, Diabetes and Metabolism60
Show all 42 subfields
- Hematology48
- Dermatology47
- Orthopedics and Sports Medicine47
- Pediatrics, Perinatology and Child Health47
- Ophthalmology41
- Obstetrics and Gynecology39
- Nephrology27
- Pharmacology27
- Rheumatology27
- Emergency Medicine22
- Reproductive Medicine22
- Otorhinolaryngology18
- Complementary and alternative medicine17
- Rehabilitation16
- Pathology and Forensic Medicine15
- Geriatrics and Gerontology13
- Immunology and Allergy13
- Critical Care and Intensive Care Medicine12
- Anesthesiology and Pain Medicine8
- Genetics8
- Hepatology7
- Gastroenterology6
- Urology5
- Internal Medicine3
- Transplantation2
- Biochemistry1
- Family Practice1
- Anatomy0
- Health Informatics0
- Microbiology0
103 ranked journals
Filters
Rank is the position by OJR within the list on screen; 1 is the highest. | OJR is field-normalized 3-year citation impact: 1.00 is the world average for papers of the same subfield, year and type, so values compare across fields. The badge is the journal’s quartile in this list. | Citations per paper over a two-year window, counted from OpenAlex. It is not field-normalized, so compare it only between journals of the same field. ▲ or ▼ is the change from 2002. This is OpenJournalRank’s own count, not Clarivate’s Journal Impact Factor. | Citable documents (articles, reviews and conference papers) published in 2000–2002, the window the 2003 OJR is computed on. A journal needs at least 30 to be ranked. | Share of the journal’s 2000–2002 papers that are free to read in any open-access form. The green OA tag next to a title marks a fully open-access journal. | List price of the article processing charge in US dollars. “$0 listed” means the listed price is zero; a dash means no price is listed. | The line is the journal’s OJR from 2000 to 2003. | Compare |
|---|---|---|---|---|---|---|---|
1CA A Cancer Journal for CliniciansOAWiley · United States | 14.57Q1 | 29.53 1.29 up from 2002 | 67 | 100% | $4,330 | ||
2Cancer CellCell Press · Netherlands | 6.16Q1 | 14.69no 2002 value | 134 | 100% | $10,400 | — | |
3Nature MedicineNature Portfolio · United States | 6.04Q1 | 13.59 0.10 down from 2002 | 1,168 | 16% | $12,690 | ||
4Journal of Clinical OncologyLippincott Williams & Wilkins · United States | 4.70Q1 | 9.96 0.32 up from 2002 | 2,032 | 7% | — | ||
5JNCI Journal of the National Cancer InstituteOxford University Press · United States | 4.23Q1 | 9.37 0.08 down from 2002 | 765 | 30% | $5,436 | ||
6Clinical Pharmacology & TherapeuticsWiley · United States | 2.67Q1 | 4.55 0.93 up from 2002 | 323 | 1% | $4,410 | ||
7Seminars in OncologyElsevier BV · United States | 2.25Q1 | 5.26 1.77 up from 2002 | 458 | 0% | $3,550 | ||
8JNCI MonographsOxford University Press · United Kingdom | 2.19Q1 | 5.31 1.92 up from 2002 | 61 | 80% | — | ||
9The Lancet OncologyElsevier BV · United Kingdom | 2.09Q1 | 5.74 4.07 up from 2002 | 298 | 1% | $7,280 | ||
10Current Opinion in OncologyLippincott Williams & Wilkins · United Kingdom | 2.07Q1 | 4.80 0.48 up from 2002 | 233 | 1% | — | ||
11Seminars in Cancer BiologyElsevier BV · United States | 2.03Q1 | 5.36 0.43 down from 2002 | 161 | 2% | $6,060 | ||
12CancerWiley · United States | 1.98Q1 | 4.12 0.58 up from 2002 | 2,675 | 61% | $4,790 | ||
13Cancer Treatment ReviewsElsevier BV · United Kingdom | 1.85Q1 | 3.60 0.22 down from 2002 | 97 | 4% | $4,910 | ||
14JBIC Journal of Biological Inorganic ChemistrySpringer Science+Business Media · Germany | 1.79Q1 | 3.18 0.48 up from 2002 | 260 | 11% | $3,990 | ||
15Psycho-OncologyWiley · United Kingdom | 1.72Q1 | 2.68 0.59 up from 2002 | 179 | 8% | $4,940 | ||
16The OncologistOAAlphaMed Press · United Kingdom | 1.63Q1 | 3.52 0.28 up from 2002 | 315 | 57% | $3,852 | ||
17The Cancer JournalLippincott Williams & Wilkins · United States | 1.58Q1 | 2.45no 2002 value | 75 | 0% | — | — | |
18Cancer Causes & ControlSpringer Science+Business Media · Netherlands | 1.55Q1 | 3.09no change | 341 | 3% | $3,890 | ||
19European Journal of CancerElsevier BV · United Kingdom | 1.53Q1 | 3.52 0.42 up from 2002 | 1,209 | 8% | $4,270 | ||
20Expert Opinion on Investigational DrugsTaylor & Francis · United Kingdom | 1.49Q1 | 3.49 0.31 up from 2002 | 489 | 2% | — | ||
21Annals of OncologyElsevier BV · Netherlands | 1.48Q1 | 3.41 0.65 up from 2002 | 1,119 | 100% | $5,080 | ||
22Critical Reviews in Oncology/HematologyElsevier BV · Netherlands | 1.48Q1 | 3.22 0.43 up from 2002 | 263 | 5% | $4,190 | ||
23British Journal of CancerSpringer Nature · United Kingdom | 1.43Q1 | 3.52 0.31 up from 2002 | 1,994 | 99% | $5,190 | ||
24Journal of Mammary Gland Biology and NeoplasiaSpringer Science+Business Media · United States | 1.43Q1 | 3.88 0.97 up from 2002 | 112 | 11% | $4,090 | ||
25International Journal of CancerWiley · United States | 1.37Q1 | 3.89 0.77 up from 2002 | 2,627 | 60% | $5,030 | ||
26Cancer ControlOASAGE Publishing · United States | 1.37Q1 | 2.96 1.45 up from 2002 | 144 | 56% | $2,650 | ||
27Diseases of the Colon & RectumLippincott Williams & Wilkins · United States | 1.32Q2 | 2.83 0.63 up from 2002 | 899 | 2% | — | ||
28Cancer NursingLippincott Williams & Wilkins · United States | 1.25Q2 | 1.85 0.40 up from 2002 | 180 | 1% | — | ||
29OncologyKarger Publishers · Switzerland | 1.21Q2 | 2.70 0.07 up from 2002 | 374 | 16% | — | ||
30Supportive Care in CancerSpringer Science+Business Media · Germany | 1.14Q2 | 1.85 0.32 up from 2002 | 239 | 2% | $4,690 | ||
31Hematology/Oncology Clinics of North AmericaElsevier BV · United States | 1.09Q2 | 1.57 0.93 down from 2002 | 211 | 0% | $3,950 | ||
32Investigational New DrugsSpringer Science+Business Media · Netherlands | 1.08Q2 | 2.20 0.77 down from 2002 | 129 | 2% | $4,690 | ||
33Journal of Inorganic BiochemistryElsevier BV · United States | 1.06Q2 | 2.31 0.26 up from 2002 | 582 | 2% | $4,220 | ||
34Surgical OncologyElsevier BV · United Kingdom | 1.02Q2 | 2.00 0.49 up from 2002 | 64 | 2% | $3,890 | ||
35Journal of Clinical PathologyBMJ · United Kingdom | 1.02Q2 | 2.13 0.07 down from 2002 | 748 | 97% | — | ||
36Cancer Immunology ImmunotherapyOASpringer Science+Business Media · Germany | 1.01Q2 | 3.52 0.65 up from 2002 | 208 | 98% | $4,590 | ||
37Inorganica Chimica ActaElsevier BV · Netherlands | 1.00Q2 | 1.97 0.48 up from 2002 | 1,492 | 5% | $3,830 | ||
38Clinical & Experimental MetastasisSpringer Science+Business Media · Netherlands | 0.98Q2 | 2.52 0.72 up from 2002 | 171 | 5% | $5,090 | ||
39Cancer InvestigationTaylor & Francis · United Kingdom | 0.97Q2 | 2.19 0.34 up from 2002 | 328 | 2% | — | ||
40Journal of ImmunotherapyLippincott Williams & Wilkins · United States | 0.97Q2 | 3.70 0.78 up from 2002 | 206 | 7% | — | ||
41Cancer Chemotherapy and PharmacologySpringer Science+Business Media · Germany | 0.94Q2 | 1.87 0.49 down from 2002 | 252 | 2% | $4,390 | ||
42Journal of Medical ScreeningSAGE Publishing · United Kingdom | 0.93Q2 | 2.10 0.45 up from 2002 | 105 | 25% | $4,150 | ||
43European Journal of Cancer PreventionLippincott Williams & Wilkins · United States | 0.92Q2 | 1.76 0.28 up from 2002 | 228 | 0% | — | ||
44Journal of Clinical Pharmacy and TherapeuticsWiley · United Kingdom | 0.89Q2 | 1.35 0.11 down from 2002 | 181 | 56% | $2,700 | ||
45Journal of Surgical OncologyWiley · United States | 0.86Q2 | 1.94 0.41 up from 2002 | 464 | 6% | $4,570 | ||
46Current Treatment Options in OncologySpringer Science+Business Media · United States | 0.83Q2 | 1.69 1.23 up from 2002 | 147 | 2% | $4,890 | ||
47Tumor BiologyOASAGE Publishing · Switzerland | 0.82Q2 | 2.66 1.14 up from 2002 | 125 | 4% | $2,000 | ||
48Journal of Cancer Research and Clinical OncologyOASpringer Science+Business Media · Germany | 0.81Q2 | 2.04 0.10 up from 2002 | 217 | 100% | $4,390 | ||
49Acta OncologicaOATaylor & Francis · United Kingdom | 0.81Q2 | 2.10 0.27 up from 2002 | 370 | 100% | — | ||
50MicrocirculationWiley · United States | 0.80Q2 | 1.69 0.38 up from 2002 | 198 | 1% | $3,920 |
Subfields of Medicine, with Oncology highlighted.
- Surgery378
- Pulmonary and Respiratory Medicine140
- Cardiology and Cardiovascular Medicine128
- Public Health, Environmental and Occupational Health128
- Oncology103
- Epidemiology89
- Infectious Diseases82
- Psychiatry and Mental health82
- Radiology, Nuclear Medicine and Imaging69
- Neurology68
- Physiology67
- Endocrinology, Diabetes and Metabolism60
- Hematology48
- Dermatology47
- Orthopedics and Sports Medicine47
- Pediatrics, Perinatology and Child Health47
- Ophthalmology41
- Obstetrics and Gynecology39
- Nephrology27
- Pharmacology27
- Rheumatology27
- Emergency Medicine22
- Reproductive Medicine22
- Otorhinolaryngology18
- Complementary and alternative medicine17
- Rehabilitation16
- Pathology and Forensic Medicine15
- Geriatrics and Gerontology13
- Immunology and Allergy13
- Critical Care and Intensive Care Medicine12
- Anesthesiology and Pain Medicine8
- Genetics8
- Hepatology7
- Gastroenterology6
- Urology5
- Internal Medicine3
- Transplantation2
- Biochemistry1
- Family Practice1
- Anatomy0
- Health Informatics0
- Microbiology0
Journals
Citations made in 2003. Corpus-wide, 70.2% of core-journal articles and reviews published that year have at least one matched reference; the share varies by journal and field.
28 additional Oncology journals with metrics are unranked under this release’s eligibility rules: a journal needs at least 30 citable documents in 2000–2002, at least 80% of them with a subfield, and a positive world-average expectation. Ranks are within the whole category; filters hide rows without re-ranking. OJR excludes self-citations.
At a glance
Indicator year: 2003. Publication window: 2000–2002. How these summaries are calculated
- Ranked journals
- 103
- Window papers (baseline)
- 47,392 +25.3% from indicator year 2000
- Median OJR
- 0.799 +46.2% from indicator year 2000
- Rising journals (2025)
- 20
Window papers are the baseline paper population: citable papers (articles, reviews and conference papers) from 2000–2002 in all journals of the world-average baseline, including non-core journals, counted by each paper’s own subfield. They are not the papers of the ranked journals alone.
| Measure | Year series | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ranked journals | 82 | 88 | 96 | 103 | 109 | 120 | 120 | 126 | 127 | 134 | 141 | 150 | 153 | 170 | 179 | 188 | 198 | 213 | 224 | 234 | 238 | 239 | 245 | 245 | 243 | 242 | |
| Window papers (baseline) | 37,821 | 41,430 | 44,340 | 47,392 | 49,058 | 53,111 | 57,002 | 62,106 | 66,087 | 71,283 | 77,009 | 82,075 | 86,189 | 88,804 | 93,912 | 98,660 | 102,921 | 105,891 | 109,984 | 115,044 | 121,890 | 139,666 | 156,942 | 167,602 | 163,907 | 160,807 | |
| Median OJR | 0.55 | 0.62 | 0.70 | 0.799 | 0.805 | 0.831 | 0.85 | 0.90 | 0.94 | 0.93 | 1.010 | 0.95 | 1.006 | 0.974 | 0.972 | 0.967 | 0.832 | 0.84 | 0.82 | 0.79 | 0.829 | 0.830 | 0.77 | 0.750 | 0.73 | 0.748 |
How to read these rankings
- OJR, the OpenJournalRank Indicator
- A field-normalized 3-year citation impact, computed from OpenAlex with the NCI3 method. It divides the citations a journal’s papers received by the world average for papers of the same subfield, year and type, so 1.00 is the world average and 2.00 means twice as many citations as expected. Because it is normalized, it can be compared across fields. Read the methodology
- Quartiles
- Q1 to Q4 split the ranked journals of the list you are viewing into four equal groups by OJR. A journal’s quartile depends on the list: the same journal can be Q1 in its subfield and Q2 among all journals.
- Impact factor (2-year)
- Citations per paper over a two-year window, counted from OpenAlex. It is easy to compare with familiar impact factors but is not field-normalized, so compare it only within a field. It is not Clarivate’s Journal Impact Factor. Why it differs from the Journal Impact Factor
- Rank ranges
- Each rank in the latest year carries a likely range from 1,000 resamples of the journal’s papers. Where two journals’ ranges overlap, the data cannot tell them apart, so treat neighbouring ranks as ties.